Evidence map›Paper›PMID 40171874›Full record

ArticleCancer medicine2025

Cancer Accumulation and Anticancer Activity of "CROX (Cluster Regulation of RUNX)" PIP in HER2-Positive Gastric Cancer Evaluated by Chicken Egg Cancer Model.

Tatsuya Masuda, Takayoshi Watanabe, Yasutoshi Tatsumi, Jason Lin, Kazuhiro Okumura, Toshinori Ozaki, Hiroshi Sugiyama, Yasuhiko Kamikubo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tatsuya MasudaDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.
Takayoshi WatanabeDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.
Yasutoshi TatsumiDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.
Jason LinDivision of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Kazuhiro OkumuraDivision of Experimental Animal Research, Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan.
Toshinori OzakiDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.
Hiroshi SugiyamaInstitute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University, Kyoto, Japan.
Yasuhiko KamikuboDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.ORCID https://orcid.org/0000-0003-2761-8508

Funding

Japan Agency for Medical Research and Development 19am0101101j0003Japan Society for the Promotion of Science 17H03597Japan Society for the Promotion of Science 20K07710Japan Society for the Promotion of Science 20K08199Japan Society for the Promotion of Science 22K07168
6 · The paper itself

Abstract

backgroundWe have focused on pyrrole-imidazole (PI) polyamide compounds, which preferentially bind to their target DNA sequences. To validate our "CROX (Cluster Regulation of RUNX)" strategy, we have created a novel PI polyamide-based inhibitor against RUNX termed Chb-M'. Recently, we have confirmed its cancer-specific uptake in mouse xenograft derived from HER2-positive gastric cancer cells. The accumulation and efficacy of Chb-M' in cancer has not yet been investigated in vivo, which is a simpler and less expensive method other than mouse xenograft models.

methodsIn the present study, we have employed the simple and versatile experimental system termed CAM (chorioallantoic membrane) model, and evaluated whether Chb-M' could have the cancer accumulation potential and anti-cancer activity.

resultsBased on our present results, gastric cancer MKN45 cells transplanted onto CAM successfully developed cancers, and the intravenously injected FITC-labeled Chb-M' obviously accumulated in these CAM cancers. As expected, the treatment of the CAM cancers with Chb-M' significantly attenuated the growth of the CAM cancers. Our present results were basically identical to those obtained from mouse xenograft model.

conclusionOur present findings strongly suggest that Chb-M' preferentially accumulates in cancer to suppress its growth, and the CAM model might serve as a valuable and promising platform to rapidly assess the cancer uptake and anti-cancer efficacy of various PI polyamide-based drug candidates.

Indexed as

Antineoplastic AgentsErb-b2 Receptor Tyrosine KinasesImidazolesNylonsPyrrolesStomach NeoplasmsAnimalsCell Line, TumorCell ProliferationChickensDisease Models, AnimalHumansMiceXenograft Model Antitumor AssaysAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImidazolesNylonsPyrrolesCAM assaycancer cell accumulationdrug deliverynuclear localizationpyrrole‐imidazole polyamideRUNX inhibitor

Identifiers

PMID40171874
PMCPMC11962651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.